Ozempic oral pill will be produced entirely in the US and distributed through more than 70,000 pharmacies in the US.

Novo Nordisk A/S is rebranding an existing, less-popular diabetes tablet as Ozempic in the US in a bid to capitalize on the ...

Novo Nordisk, which makes the GLP-1 semaglutide medications Ozempic and Wegovy, announced that it’s rolling out an “Ozempic ...

Novo Nordisk (CPSE:NOVO B) is rolling out its oral Ozempic (semaglutide) tablet across the US as the only FDA approved oral GLP-1 for adults with type 2 diabetes. The company plans broad distribution ...

Novo Nordisk said April 23 it plans to seek expanded FDA approval for its Ozempic pill in the second half of 2026, which would make the drug the first oral GLP-1 approved for children and adolescents ...

Novo Nordisk is relaunching a less-popular diabetes tablet as Ozempic in the US, aiming to leverage the brand's strong ...

The newly approved oral formulation features a smaller pill size in 1.5mg, 4mg, and 9mg strengths while maintaining the efficacy and safety profile of the previous oral semaglutide version.

Novo Nordisk (NVO) stock is in focus as the company plans to launch Ozempic pill for children with type 2 diabetes after a ...

Novo Nordisk will launch its oral Ozempic pill for type 2 diabetes in the U.S. next week, offering competitive pricing and ...

Novo Nordisk (NYSE:NVO) is advancing the launch of an oral version of Ozempic, expanding its GLP-1 diabetes franchise beyond injectable formats. The company is also seeking regulatory approvals to ...

TD Cowen downgraded Novo Nordisk to hold. Novo Nordisk on Tuesday received a broker downgrade, with the analysts arguing that its status in a duopoly in both diabetes and weight loss are under threat.

Hershey says it's benefiting from the growing use of GLP-1 weight-loss drugs even as people cut down on snacks. Here's why.